$VNDA
Vanda Pharmaceuticals Inc.

2021 Q4 Form 10-Q Financial Statement

#000134717821000032 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $68.02M $70.10M $60.31M
YoY Change 0.54% 16.23% 1.38%
Cost Of Revenue $6.236M $6.797M $5.900M
YoY Change -2.71% 15.2% -13.01%
Gross Profit $61.78M $63.30M $54.04M
YoY Change 1.5% 17.13% 3.28%
Gross Profit Margin 90.83% 90.3% 89.61%
Selling, General & Admin $33.45M $32.46M $34.00M
YoY Change -5.97% -4.54% 12.51%
% of Gross Profit 54.14% 51.27% 62.92%
Research & Development $985.0K $19.65M $12.30M
YoY Change -92.51% 59.81% 8.38%
% of Gross Profit 1.59% 31.05% 22.76%
Depreciation & Amortization $706.0K $708.0K $700.0K
YoY Change -11.75% 1.14% 16.67%
% of Gross Profit 1.14% 1.12% 1.3%
Operating Expenses $33.35M $52.11M $46.30M
YoY Change -32.07% 12.55% 11.38%
Operating Profit $28.44M $10.82M $7.742M
YoY Change 172.09% 39.74% -28.04%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$26.00K -$97.00K $660.0K
YoY Change -105.53% -114.7% -56.58%
Pretax Income $8.610M $10.72M $8.401M
YoY Change -21.15% 27.63% -31.57%
Income Tax $1.532M $3.000M $2.500M
% Of Pretax Income 17.79% 27.98% 29.76%
Net Earnings $7.078M $7.771M $5.947M
YoY Change -13.58% 30.67% -94.08%
Net Earnings / Revenue 10.41% 11.09% 9.86%
Basic Earnings Per Share $0.14 $0.11
Diluted Earnings Per Share $123.7K $0.14 $0.11
COMMON SHARES
Basic Shares Outstanding 55.71M shares 55.67M shares 54.67M shares
Diluted Shares Outstanding 57.04M shares 55.21M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $432.8M $406.0M $348.5M
YoY Change 17.7% 16.47% 46.58%
Cash & Equivalents $52.07M $50.52M $56.97M
Short-Term Investments $380.7M $355.4M $291.6M
Other Short-Term Assets $12.00M $13.44M $11.70M
YoY Change 18.77% 14.89% -18.75%
Inventory $1.025M $902.0K $1.322M
Prepaid Expenses
Receivables $32.47M $41.50M $28.03M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $478.3M $461.8M $389.5M
YoY Change 16.9% 18.55% 39.11%
LONG-TERM ASSETS
Property, Plant & Equipment $3.113M $3.318M $3.921M
YoY Change -24.73% -15.38% -5.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $83.03M $84.61M $90.20M
YoY Change -5.87% -6.2% -3.63%
Total Long-Term Assets $115.5M $118.0M $126.4M
YoY Change -7.1% -6.66% -35.01%
TOTAL ASSETS
Total Short-Term Assets $478.3M $461.8M $389.5M
Total Long-Term Assets $115.5M $118.0M $126.4M
Total Assets $593.8M $579.8M $515.9M
YoY Change 11.31% 12.38% 8.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.873M $6.061M $5.200M
YoY Change 1.26% 16.56% -10.34%
Accrued Expenses $68.55M $65.59M $23.90M
YoY Change 14.63% 174.42% -55.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $74.42M $72.00M $61.36M
YoY Change 12.87% 17.34% 2.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.390M $3.992M $2.415M
YoY Change 59.23% 65.3% 220.72%
Total Long-Term Liabilities $4.390M $3.992M $2.415M
YoY Change 59.23% 65.3% 220.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $74.42M $72.00M $61.36M
Total Long-Term Liabilities $4.390M $3.992M $2.415M
Total Liabilities $88.86M $86.45M $75.33M
YoY Change 10.82% 14.75% 2.44%
SHAREHOLDERS EQUITY
Retained Earnings -$164.2M -$171.3M -$205.5M
YoY Change -16.8% -16.67% -8.61%
Common Stock $669.3M $664.5M $645.7M
YoY Change 2.91% 2.9% 3.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $504.9M $493.3M $440.6M
YoY Change
Total Liabilities & Shareholders Equity $593.8M $579.8M $515.9M
YoY Change 11.31% 12.38% 8.74%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income $7.078M $7.771M $5.947M
YoY Change -13.58% 30.67% -94.08%
Depreciation, Depletion And Amortization $706.0K $708.0K $700.0K
YoY Change -11.75% 1.14% 16.67%
Cash From Operating Activities $26.61M $9.397M $9.400M
YoY Change 37.86% -0.03% 56.67%
INVESTING ACTIVITIES
Capital Expenditures -$134.0K $10.00K -$200.0K
YoY Change -86.6% -105.0% -33.33%
Acquisitions
YoY Change
Other Investing Activities -$25.86M -$16.60M -$47.60M
YoY Change 64.74% -65.13% 250.0%
Cash From Investing Activities -$26.00M -$16.59M -$47.80M
YoY Change 55.68% -65.3% 243.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.041M 371.0K 100.0K
YoY Change -25.64% 271.0% -80.0%
NET CHANGE
Cash From Operating Activities 26.61M 9.397M 9.400M
Cash From Investing Activities -26.00M -16.59M -47.80M
Cash From Financing Activities 1.041M 371.0K 100.0K
Net Change In Cash 1.650M -6.820M -38.30M
YoY Change -58.75% -82.19% 417.57%
FREE CASH FLOW
Cash From Operating Activities $26.61M $9.397M $9.400M
Capital Expenditures -$134.0K $10.00K -$200.0K
Free Cash Flow $26.74M $9.387M $9.600M
YoY Change 31.73% -2.22% 52.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001347178
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4136000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9580000 USD
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34186
dei Entity Registrant Name
EntityRegistrantName
VANDA PHARMACEUTICALS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
03-0491827
dei Entity Address Address Line1
EntityAddressAddressLine1
2200 Pennsylvania Avenue NW
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300E
dei Entity Address City Or Town
EntityAddressCityOrTown
Washington
dei Entity Address State Or Province
EntityAddressStateOrProvince
DC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20037
dei City Area Code
CityAreaCode
202
dei Local Phone Number
LocalPhoneNumber
734-3400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
VNDA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55712230 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50522000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61031000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
355446000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
306709000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
41496000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30036000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
902000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1280000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13442000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10089000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
461808000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
409145000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3318000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10459000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20450000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21559000 USD
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
76105000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
81516000 USD
CY2021Q3 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
8506000 USD
CY2020Q4 vnda Inventory And Other Non Current
InventoryAndOtherNonCurrent
6641000 USD
CY2021Q3 us-gaap Assets
Assets
579767000 USD
CY2020Q4 us-gaap Assets
Assets
533456000 USD
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31820000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31509000 USD
CY2021Q3 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
40177000 USD
CY2020Q4 vnda Product Revenue Allowances Current
ProductRevenueAllowancesCurrent
34427000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
71997000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65936000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10457000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11497000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3992000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2757000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
86446000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
80190000 USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55708730 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55708730 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54865092 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54865092 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
56000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
55000 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
664408000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
650300000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
111000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
239000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-171254000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197328000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
493321000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
453266000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
579767000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
533456000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70095000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60308000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
200663000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
180515000 USD
CY2021Q3 us-gaap Revenues
Revenues
70095000 USD
CY2020Q3 us-gaap Revenues
Revenues
60308000 USD
us-gaap Revenues
Revenues
200663000 USD
us-gaap Revenues
Revenues
180515000 USD
CY2021Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
6797000 USD
CY2020Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
5898000 USD
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
19393000 USD
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
16952000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19653000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12298000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56032000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40728000 USD
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
32456000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34001000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
90600000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
104939000 USD
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
370000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
369000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1109000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1108000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
59276000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
52566000 USD
us-gaap Costs And Expenses
CostsAndExpenses
167134000 USD
us-gaap Costs And Expenses
CostsAndExpenses
163727000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
10819000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
7742000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
33529000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
16788000 USD
CY2021Q3 us-gaap Other Income
OtherIncome
-97000 USD
CY2020Q3 us-gaap Other Income
OtherIncome
659000 USD
us-gaap Other Income
OtherIncome
225000 USD
us-gaap Other Income
OtherIncome
3943000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
10722000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8401000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
33754000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
20731000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2951000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2454000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7680000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5584000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
7771000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
5947000 USD
us-gaap Net Income Loss
NetIncomeLoss
26074000 USD
us-gaap Net Income Loss
NetIncomeLoss
15147000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55668156 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54666128 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55467528 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54325832 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57040736 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55209032 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56818295 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55054772 shares
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
7771000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
5947000 USD
us-gaap Net Income Loss
NetIncomeLoss
26074000 USD
us-gaap Net Income Loss
NetIncomeLoss
15147000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-17000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
32000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-48000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
29000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
33000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-323000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-102000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
130000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
8000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-74000 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-22000 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
29000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
8000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-217000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-128000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
130000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7779000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5730000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
25946000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
15277000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
453266000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1849000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3909000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
8650000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-47000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
467627000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
289000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3740000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
9653000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-89000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
481220000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
371000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3951000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
7771000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
8000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
493321000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
410945000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
479000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3944000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
486000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
532000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
416386000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3600000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3069000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
8714000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-185000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
431584000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
123000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3135000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
5947000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-217000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
440572000 USD
us-gaap Net Income Loss
NetIncomeLoss
26074000 USD
us-gaap Net Income Loss
NetIncomeLoss
15147000 USD
us-gaap Depreciation
Depreciation
1026000 USD
us-gaap Depreciation
Depreciation
1043000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
11600000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
10148000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1451000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
175000 USD
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
12000 USD
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
229000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1109000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1108000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
5432000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
3793000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1222000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1361000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11484000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1774000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2932000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2897000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2156000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3128000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
860000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1408000 USD
vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
5417000 USD
vnda Increase Decrease Product Revenue Allowances
IncreaseDecreaseProductRevenueAllowances
874000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
37607000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
32473000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
418000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
829000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
315187000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
264112000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
264907000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
240128000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50698000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24813000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61613000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2509000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4202000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2509000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4202000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10572000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11903000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45650000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51041000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57553000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management’s evaluation could change. Actual results could differ from those estimates.</span></div>
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50522000 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56973000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51041000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57553000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70095000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60308000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
200663000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
180515000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
355343000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
135000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
32000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
355446000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
306504000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
216000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
306709000 USD
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
355446000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
306709000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1214000 USD
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
66000 USD
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
902000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
902000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1280000 USD
CY2021Q3 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
2016000 USD
CY2020Q4 vnda Inventory Raw Materials Net Of Reserves Non Current
InventoryRawMaterialsNetOfReservesNonCurrent
744000 USD
CY2021Q3 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
4233000 USD
CY2020Q4 vnda Inventory Work In Process Net Of Reserves Non Current
InventoryWorkInProcessNetOfReservesNonCurrent
4045000 USD
CY2021Q3 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
1032000 USD
CY2020Q4 vnda Inventory Finished Goods Net Of Reserves Non Current
InventoryFinishedGoodsNetOfReservesNonCurrent
302000 USD
CY2021Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
7281000 USD
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
5091000 USD
CY2021Q3 vnda Inventory
Inventory
8183000 USD
CY2020Q4 vnda Inventory
Inventory
6371000 USD
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5052000 USD
CY2021Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
6061000 USD
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5817000 USD
CY2021Q3 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
9010000 USD
CY2020Q4 vnda Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
6173000 USD
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7371000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5434000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10951000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2295000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2117000 USD
CY2021Q3 vnda Accrued Milestone Obligations Under License Agreements
AccruedMilestoneObligationsUnderLicenseAgreements
350000 USD
CY2020Q4 vnda Accrued Milestone Obligations Under License Agreements
AccruedMilestoneObligationsUnderLicenseAgreements
350000 USD
CY2021Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1299000 USD
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1049000 USD
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31820000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31509000 USD
vnda Agreements For Clinical And Marketing Services Termination Notice Period
AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod
P90D
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
33000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
81000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
78000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
158000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
111000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
239000 USD
vnda Sharebased Compensation Arrangementby Share Based Payment Award Options Vesting Period Number Of Equal Monthly Installments
SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments
36 installment
vnda Share Based Compensation Option Awards Contractual Term
ShareBasedCompensationOptionAwardsContractualTerm
P10Y
vnda Share Based Compensation Arrangementby Share Based Payment Annual Award Vesting Period Employeesand New Directors
ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors
P4Y
vnda Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
0.25
vnda Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
0.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.53
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2500000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4200000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11600000 USD
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3951000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3135000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10148000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.51
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0075
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2500000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7700000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5600000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0114
CY2021Q3 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
100000 USD
CY2020Q3 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
500000 USD
us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
200000 USD
us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
1600000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
7771000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
5947000 USD
us-gaap Net Income Loss
NetIncomeLoss
26074000 USD
us-gaap Net Income Loss
NetIncomeLoss
15147000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55668156 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54666128 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1350767 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55467528 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54325832 shares
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1372580 shares
CY2020Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
542904 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
728940 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57040736 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55209032 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56818295 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55054772 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2233806 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3898896 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2194547 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3602648 shares

Files In Submission

Name View Source Status
0001347178-21-000032-index-headers.html Edgar Link pending
0001347178-21-000032-index.html Edgar Link pending
0001347178-21-000032.txt Edgar Link pending
0001347178-21-000032-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vnda-20210930.htm Edgar Link pending
vnda-20210930.xsd Edgar Link pending
vnda-20210930_cal.xml Edgar Link unprocessable
vnda-20210930_def.xml Edgar Link unprocessable
vnda-20210930_htm.xml Edgar Link completed
vnda-20210930_lab.xml Edgar Link unprocessable
vnda-20210930_pre.xml Edgar Link unprocessable
vndaex311930202110q.htm Edgar Link pending
vndaex312930202110q.htm Edgar Link pending
vndaex321930202110q.htm Edgar Link pending